141 related articles for article (PubMed ID: 10811672)
1. Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation.
Nieto Y; Cagnoni PJ; Nawaz S; Shpall EJ; Yerushalmi R; Cook B; Russell P; McDermit J; Murphy J; Bearman SI; Jones RB
J Clin Oncol; 2000 May; 18(10):2070-80. PubMed ID: 10811672
[TBL] [Abstract][Full Text] [Related]
2. P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support.
Hensel M; Schneeweiss A; Sinn HP; Egerer G; Solomayer E; Haas R; Bastert G; Ho AD
Int J Cancer; 2002 Jul; 100(3):290-6. PubMed ID: 12115543
[TBL] [Abstract][Full Text] [Related]
3. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant.
Nieto Y; Cagnoni PJ; Shpall EJ; Xu X; Murphy J; Vredenburgh J; Chao NJ; Bearman SI; Jones RB
Clin Cancer Res; 1999 Nov; 5(11):3425-31. PubMed ID: 10589754
[TBL] [Abstract][Full Text] [Related]
4. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation.
Kim YS; Konoplev SN; Montemurro F; Hoy E; Smith TL; Rondón G; Champlin RE; Sahin AA; Ueno NT
Clin Cancer Res; 2001 Dec; 7(12):4008-12. PubMed ID: 11751494
[TBL] [Abstract][Full Text] [Related]
5. Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy.
Schneeweiss A; Goerner R; Hensel MA; Lauschner I; Sinn P; Kaul S; Egerer G; Beldermann F; Geberth M; Solomayer E; Grischke EM; Haas R; Ho AD; Bastert G
Biol Blood Marrow Transplant; 2001; 7(6):332-42. PubMed ID: 11464976
[TBL] [Abstract][Full Text] [Related]
6. High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival.
Somlo G; Doroshow JH; Forman SJ; Odom-Maryon T; Lee J; Chow W; Hamasaki V; Leong L; Morgan R; Margolin K; Raschko J; Shibata S; Tetef M; Yen Y; Simpson J; Molina A
J Clin Oncol; 1997 Aug; 15(8):2882-93. PubMed ID: 9256132
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
8. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes.
Bearman SI; Overmoyer BA; Bolwell BJ; Taylor CW; Shpall EJ; Cagnoni PJ; Mechling BE; Ronk B; Barón AE; Purdy MH; Ross M; Jones RB
Bone Marrow Transplant; 1997 Dec; 20(11):931-7. PubMed ID: 9422471
[TBL] [Abstract][Full Text] [Related]
9. Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support.
Bewick M; Chadderton T; Conlon M; Lafrenie R; Morris D; Stewart D; Glück S
Bone Marrow Transplant; 1999 Aug; 24(4):377-84. PubMed ID: 10467326
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
Hanrahan EO; Broglio K; Frye D; Buzdar AU; Theriault RL; Valero V; Booser DJ; Singletary SE; Strom EA; Gajewski JL; Champlin RE; Hortobagyi GN
Cancer; 2006 Jun; 106(11):2327-36. PubMed ID: 16639731
[TBL] [Abstract][Full Text] [Related]
11. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
Cheng YC; Rondón G; Yang Y; Smith TL; Gajewski JL; Donato ML; Shpall EJ; Jones R; Hortobagyi GN; Champlin RE; Ueno NT
Biol Blood Marrow Transplant; 2004 Nov; 10(11):794-804. PubMed ID: 15505610
[TBL] [Abstract][Full Text] [Related]
12. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
Berry DA; Muss HB; Thor AD; Dressler L; Liu ET; Broadwater G; Budman DR; Henderson IC; Barcos M; Hayes D; Norton L
J Clin Oncol; 2000 Oct; 18(20):3471-9. PubMed ID: 11032587
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer.
Sawaki M; Ito Y; Akiyama F; Tokudome N; Horii R; Mizunuma N; Takahashi S; Horikoshi N; Imai T; Nakao A; Kasumi F; Sakamoto G; Hatake K
Breast Cancer; 2006; 13(2):172-8. PubMed ID: 16755113
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer.
Marks JR; Humphrey PA; Wu K; Berry D; Bandarenko N; Kerns BJ; Iglehart JD
Ann Surg; 1994 Apr; 219(4):332-41. PubMed ID: 7909221
[TBL] [Abstract][Full Text] [Related]
15. Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell support.
Hensel M; Schneeweiss A; Sinn HP; Egerer G; Kornacker M; Solomayer E; Haas R; Bastert G; Ho AD
Stem Cells; 2002; 20(1):32-40. PubMed ID: 11796920
[TBL] [Abstract][Full Text] [Related]
16. Microsatellite instability predicts poor short-term survival in patients with advanced breast cancer after high-dose chemotherapy and autologous stem-cell transplantation.
Wild PJ; Reichle A; Andreesen R; Röckelein G; Dietmaier W; Rüschoff J; Blaszyk H; Hofstädter F; Hartmann A
Clin Cancer Res; 2004 Jan; 10(2):556-64. PubMed ID: 14760077
[TBL] [Abstract][Full Text] [Related]
17. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
18. Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy.
Bitran JD; Samuels B; Trujillo Y; Klein L; Schroeder L; Martinec J
Clin Cancer Res; 1996 Sep; 2(9):1509-13. PubMed ID: 9816327
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry.
Pedrazzoli P; Martinelli G; Gianni AM; Da Prada GA; Ballestrero A; Rosti G; Frassineti GL; Aieta M; Secondino S; Cinieri S; Fedele R; Bengala C; Bregni M; Grasso D; De Giorgi U; Lanza F; Castagna L; Bruno B; Martino M;
Biol Blood Marrow Transplant; 2014 Apr; 20(4):501-6. PubMed ID: 24374214
[TBL] [Abstract][Full Text] [Related]
20. Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients.
Tokatli F; Altaner S; Uzal C; Ture M; Kocak Z; Uygun K; Bilgi S
Exp Oncol; 2005 Jun; 27(2):145-9. PubMed ID: 15995634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
